Monopar Therapeutics Inc expected to post a loss of 22  cents a share - Earnings Preview

Monopar Therapeutics

09/05/2022 19:31

* Monopar Therapeutics Inc  MNPR.OQ   MNPR.O  is expected
to show
no change in quarterly revenue when it reports  results on May
11 (estimated). 
    * ​Refinitiv's mean analyst estimate for Monopar
Therapeutics Inc
is for a loss of 22 cents per share. For the same quarter last
year, the company reported a loss of 16 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Monopar
Therapeutics Inc is $22​, above​ its last closing price
of $2.18. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021              -0.19      -0.21     Missed  -10.5
 Sep. 30 2021  -0.19       -0.21      -0.20     Beat    5.9
 Jun. 30 2021  -0.19       -0.19      -0.17     Beat    11.7​
 Mar. 31 2021  -0.19       -0.19      -0.16     Beat    14.3
 ​​Dec.        -0.17       -0.19      -0.20     Missed  -6.7
 31 2020                                                
 Sep. 30 2020  -0.15       -0.15      -0.15     Met     2.2​
 Jun. 30 2020  -0.09       -0.09      -0.14     Missed  -55.6
 Mar. 31 2020  -0.11       -0.11      -0.10     Beat    9.1
 This summary was machine generated May 9 at 18:31 GMT.  All
figures in US dollars  unless otherwise stated